Korea Investment CORP boosted its position in shares of Core Laboratories N.V. (NYSE:CLB) by 22.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 53,600 shares of the oil and gas company’s stock after buying an additional 10,000 shares during the period. Korea Investment CORP’s holdings in Core Laboratories N.V. were worth $5,428,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. increased its stake in Core Laboratories N.V. by 0.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 114,731 shares of the oil and gas company’s stock worth $13,772,000 after buying an additional 556 shares in the last quarter. Creative Planning increased its stake in Core Laboratories N.V. by 1.9% in the first quarter. Creative Planning now owns 1,730 shares of the oil and gas company’s stock worth $200,000 after buying an additional 33 shares in the last quarter. Gulf International Bank UK Ltd increased its stake in Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock worth $1,553,000 after buying an additional 400 shares in the last quarter. Bank of Montreal Can increased its stake in Core Laboratories N.V. by 462.4% in the first quarter. Bank of Montreal Can now owns 163,920 shares of the oil and gas company’s stock worth $18,937,000 after buying an additional 134,773 shares in the last quarter. Finally, Atria Investments LLC increased its stake in Core Laboratories N.V. by 11.2% in the first quarter. Atria Investments LLC now owns 3,839 shares of the oil and gas company’s stock worth $443,000 after buying an additional 388 shares in the last quarter.

Core Laboratories N.V. (CLB) opened at 92.92 on Friday. Core Laboratories N.V. has a 52 week low of $92.81 and a 52 week high of $125.83. The company has a market capitalization of $4.10 billion, a P/E ratio of 57.01 and a beta of 1.60. The company’s 50 day moving average price is $101.46 and its 200-day moving average price is $108.84.

Core Laboratories N.V. (NYSE:CLB) last released its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.01. The business had revenue of $163.90 million during the quarter, compared to analysts’ expectations of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.35 EPS. Equities research analysts expect that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 14th. Stockholders of record on Monday, July 17th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, July 13th. This represents a $2.20 annualized dividend and a dividend yield of 2.37%. Core Laboratories N.V.’s dividend payout ratio is currently 134.15%.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/korea-investment-corp-purchases-10000-shares-of-core-laboratories-n-v-nyseclb/1477013.html.

A number of equities research analysts have issued reports on CLB shares. Loop Capital upgraded Core Laboratories N.V. from a “hold” rating to a “buy” rating and boosted their price target for the company from $125.00 to $130.00 in a research note on Friday, April 21st. Zacks Investment Research upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Friday, April 21st. ABN Amro upgraded Core Laboratories N.V. to a “hold” rating in a research note on Friday, April 21st. Scotiabank set a $136.00 price target on Core Laboratories N.V. and gave the company a “hold” rating in a research note on Saturday, April 22nd. Finally, ValuEngine downgraded Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, June 6th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. Core Laboratories N.V. currently has an average rating of “Hold” and an average target price of $117.17.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.